Ascletis Pharma Inc. Stock

Equities

1672

KYG0520K1094

Pharmaceuticals

Market Closed - Hong Kong S.E. 04:08:13 2024-06-24 am EDT 5-day change 1st Jan Change
0.86 HKD -4.44% Intraday chart for Ascletis Pharma Inc. -11.34% -41.10%

Financials

Sales 2024 * - Sales 2025 * - Capitalization 848M 117M 912M
Net income 2024 * -219M -30.17M -235M Net income 2025 * -242M -33.34M -260M EV / Sales 2024 * -
Net cash position 2024 * 2B 276M 2.15B Net cash position 2025 * 1.7B 234M 1.82B EV / Sales 2025 * -
P/E ratio 2024 *
-4.13 x
P/E ratio 2025 *
-3.68 x
Employees 219
Yield 2024 *
-
Yield 2025 *
-
Free-Float 27.46%
More Fundamentals * Assessed data
Dynamic Chart
Ascletis Pharma Inc. Announces Presentation Designing Positive Interim 12-Week Results from Phase II Clinical Trial of ASC41 in Patients with Biopsy- Confirmed Mash At EASL Congress 2024 CI
Ascletis Discontinues Trials of FXR Agonist for Biliary Cholangitis, NASH and Hepatitis B Virus MT
Ascletis Pharma Inc. Announces Strategic Decisions on FXR Agonist ASC42 CI
Ascletis Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Ascletis Pharma Inc. Announces Poster Presentation of Phase II Study Final Results of FASN Inhibitor ASC40 for Treatment of Acne at 2024 AAD Annual Meeting CI
Ascletis Pharma Doses First Patient in Phase 3 Clinical Trial of Acne Vulgaris Drug MT
Ascletis Pharma Inc. Announces Dosing of the First Patient in Phase III Clinical Trial of Asc40 (Denifanstat) for Treatment of Acne CI
Ascletis Pharma's Liver Treatment Reduces Fat in 9 of 10 Participants During Phase 2 Trial MT
Ascletis Pharma Inc. Announces Positive Interim Results from 52-Week Phase Ii Clinical Trial of Once-Daily Asc41 Tablet in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis CI
Ascletis Pharma Gets Nod to Trial Acne Drug MT
Ascletis Pharma Inc. Announces Initiation of Phase III Clinical Trial of ASC40 (Denifanstat) for Treatment of Acne CI
Ascletis Pharma Presents Data on Studies for Liver Treatments at US Liver Disease Meet MT
Ascletis Pharma Publishes Results of Gannex's Fatty Liver Medication MT
Ascletis Pharma Presents Data in Germany from Phase 2 Study on Anti-Acne Drug MT
Ascletis Pharma Finds Envafolimab Safe to Use in Study MT
More news
1 day-4.44%
1 week-11.34%
Current month-28.93%
1 month-31.75%
3 months-43.42%
6 months-41.10%
Current year-41.10%
More quotes
1 week
0.82
Extreme 0.82
0.99
1 month
0.82
Extreme 0.82
1.29
Current year
0.82
Extreme 0.82
1.93
1 year
0.82
Extreme 0.82
2.30
3 years
0.82
Extreme 0.82
7.26
5 years
0.82
Extreme 0.82
7.26
10 years
0.82
Extreme 0.82
14.90
More quotes
Managers TitleAgeSince
Chief Executive Officer 61 -
Chief Tech/Sci/R&D Officer - -
Chief Tech/Sci/R&D Officer - 19-10-06
Members of the board TitleAgeSince
Chief Executive Officer 61 -
Director/Board Member 51 18-03-31
Chief Operating Officer 50 19-03-12
More insiders
Date Price Change Volume
24-06-24 0.86 -4.44% 1 483 000
24-06-21 0.9 -1.10% 631,000
24-06-20 0.91 -5.21% 1,492,000
24-06-19 0.96 0.00% 853,000
24-06-18 0.96 -1.03% 1,095,000

Delayed Quote Hong Kong S.E., June 24, 2024 at 04:08 am EDT

More quotes
Ascletis Pharma Inc is a China-based investment holding company principally engaged in the research, development, production, marketing and sales of pharmaceutical products. The Company mainly focuses on viral diseases, non-alcoholic steatohepatitis (NASH) and oncology fields. Viral diseases pipeline includes Ritonavir, Ravidasvir, Danoprevir and others. NASH pipeline includes ASC40, ASC41, ASC42 and others. Oncology pipeline includes ASC60, ASC61 and others.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.8373 CNY
Average target price
2.752 CNY
Spread / Average Target
+228.69%
Consensus